Thus, to explore the novel mechanisms of resistance to PARP inhibitors, we constructed BRCA1 KO pancreatic cancer cells (C1 cells) and then derived an olaparib-resistant clone (C1/OLA cells) from these cells. The gene discussed is PARP1; the disease is pancreatic neoplasm.